Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Search
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic
Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Life Forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom
Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial
Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.
Our Curiosity Never Stops | Boehringer Ingelheim US
Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Improving Access to Clinical Trials
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
What you need to know about counterfeit medicines
Understand the risk of counterfeit medication.
OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US
Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial